文献速递炎症性肠病

妊娠期炎症性肠病女性使用维得利珠单抗与乌司奴单抗及其宫内暴露婴儿的药物水平

Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-03-15

多中心前瞻性观察队列纳入102例妊娠或孕前使用维得利珠单抗(n=58)或乌司奴单抗的炎症性肠病女性,监测孕期及产后药物谷浓度。维得利珠单抗水平随体重增加而下降,乌司奴单抗水平保持稳定;婴儿药物不可检测中位时间维得利珠单抗为11周(范围5-19周,n=32),乌司奴单抗为14周(范围9-36周,n=17)。妊娠及婴儿结局良好,未发现安全性信号。

要点

  • 维得利珠单抗水平随孕期体重增加而下降,乌司奴单抗水平保持稳定。
  • 88%(32/41)维得利珠单抗暴露与67%(17/30)乌司奴单抗暴露婴儿在15周龄时药物不可检测。
  • 20例药物不可检测婴儿接种轮状病毒疫苗,未报告不良反应。

核心结论

  • 母体维得利珠单抗水平随孕期下降,而乌司奴单抗水平保持稳定。
  • 大多数维得利珠单抗暴露婴儿和约半数乌司奴单抗暴露婴儿在15周龄时药物水平不可检测。
  • 未发现令人担忧的母体或婴儿安全性信号。

研究设计与样本

  • 多中心前瞻性观察队列研究,纳入妊娠或孕前使用维得利珠单抗或乌司奴单抗的炎症性肠病女性,共102例(维得利珠单抗n=58)。
  • 在孕前、孕期各三月期及产后记录谷浓度、临床和生化数据,分娩时测母体及脐血药物水平,婴儿随访至药物不可检测,结局评估至2岁。

主要发现

  • 多数母亲在孕期维持临床和生化缓解。
  • 母体维得利珠单抗水平随孕期体重增加而非孕周增加而下降。
  • 婴儿药物不可检测中位时间维得利珠单抗为11周(范围5-19周,n=32),短于乌司奴单抗的14周(范围9-36周,n=17),并与婴儿分娩时药物水平正相关。
  • 15周龄时维得利珠单抗暴露婴儿32/41(88%)和乌司奴单抗暴露婴儿17/30(67%)药物水平不可检测。
  • 妊娠及婴儿结局良好;20例药物不可检测婴儿接种轮状病毒疫苗,未报告不良反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant after in utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab levels and the time at which infant drug levels become undetectable. METHODS: This multicenter prospective observational cohort study recruited pregnant or preconception women with inflammatory bowel disease receiving vedolizumab or ustekinumab. Trough drug levels, clinical data, and biochemical data were documented preconception, during each trimester of pregnancy, and postpartum. Maternal and cord blood drug levels were measured at delivery and in infants until undetectable. Infant outcomes were assessed until 2 years of age. RESULTS: A total of 102 participants (vedolizumab, n = 58) were included. The majority of mothers were, and remained, in clinical and biochemical remission. Maternal vedolizumab levels decreased over the course of pregnancy in association with increasing weight, rather than increasing gestation. Maternal ustekinumab levels remained stable. The median time to drug becoming undetectable in the infant was shorter for vedolizumab (11 wk; range, 5-19 wk; n = 32) than ustekinumab (14 wk; range, 9-36 wk; n = 17) and correlated positively with infant delivery level. Thirty-two of 41 (88%) and 17 of 30 (67%) vedolizumab- and ustekinumab-exposed infants had undetectable drug levels by 15 weeks of age, respectively. Pregnancy and infant outcomes were favorable. Twenty infants with undetectable drug levels received the rotavirus vaccine, with no adverse reactions reported. CONCLUSIONS: Maternal vedolizumab levels decreased, whereas ustekinumab levels remained stable over the course of pregnancy. Most vedolizumab- and approximately half of ustekinumab-exposed infants had undetectable drug levels by 15 weeks of age. No concerning maternal or infant safety signals were identified.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Prentice R, Flanagan E, Wright EK, et al. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. Clin Gastroenterol Hepatol. 2024. PMID: 38492905. doi:10.1016/j.cgh.2024.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。